I-Ningbo Cland Medical Instruments Co., Ltd. ingenye yezinto ezine-Vula Ukuqoqwa Kweqoqo Legazi Legazi ezihola phambili e-China. Yimboni & umphakeli onguchwepheshe wokwenza Vula Ukuqoqwa Kweqoqo Legazi Legazi. Nikeza ikhwalithi ephezulu Vula Ukuqoqwa Kweqoqo Legazi Legazi ngentengo ephansi eshibhile. The HIV community has been whispering about it for months, and now it's finally here: The U.S. Food and Drug Administration has approved Atripla (efavirenz/FTC/tenofovir), the first pill to combine HIV meds from two different drug classes. All three of the meds that make up Atripla have been around for years -- in fact, the combination of efavirenz (Sustiva, Stocrin) + Truvada (tenofovir/FTC) is one of the most commonly prescribed first-line HIV treatment regimens in the United States. Atripla combines them all into a single pill that only needs to be taken once a day. It's not a revolutionary advance in HIV treatment, but it does set a new high-water mark for convenience -- and it will reduce the number of health insurance copays for many people who are currently taking efavirenz + Truvada separately.